ArticleChinese herbal medicines2024
Biosynthesis of natural products from medicinal plants: Challenges, progress and prospects.
Article in Chinese herbal medicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Genome-wide identification of the GRF gene family and response to cold stress in astragalus (Astragalus membranaceus).BMC genomics · 2026Article
- The pathological mechanisms and potential therapeutic strategies for renal anemia.Frontiers in pharmacology · 2026Review
- First identification of the rare FH-Q185R germline mutation in a Chinese HLRCC patient: A case report and literature review.SAGE open medical case reports · 2026Article
- Genome-wide identification and expression analyses of HSP90 genes in cassava (Manihot esculenta).Journal, genetic engineering & biotechnology · 2025Review
- Genome-Wide Transcriptome Analysis Reveals GRF Transcription Factors Involved in Methyl Jasmonate-Induced Flavonoid Biosynthesis inPlants (Basel, Switzerland) · 2025Article
- Taxifolin attenuates liver fibrosis by regulating the phosphorylation of NDRG1 at Thr328Acta pharmaceutica Sinica. B · 2025Article
- Harnessing the therapeutic value of Tanshinone IIA: a breakthrough therapy in cardiovascular diseases.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.